# Basal Cell Carcinoma

Manage basal cell carcinoma by confirming clinically uncertain lesions histologically, separating low-risk from high-risk or recurrent tumors, selecting margin-controlled surgery when tissue preservation and clearance matter, and escalating unresectable disease to Hedgehog inhibition or cemiplimab.

**Clinical question:** How should physicians diagnose, risk-stratify, treat, and surveil basal cell carcinoma?

Updated: 2026-08-24T17:03:21.432862+00:00

## What matters in practice
- Biopsy clinically equivocal lesions; dermoscopy can support diagnosis and may help predict histopathologic subtype, but histopathology establishes the diagnosis when uncertainty remains. [5][15]
- Use margin-controlled surgery for high-risk, recurrent, or anatomically critical-site BCC; complete surgical treatment is first-line for most tumors. [5][6]
- Features that should move a lesion out of routine low-risk management include diameter greater than 2 cm, central-face, ear, or scalp location, poorly defined borders, recurrence, morpheaform, infiltrative, micronodular, or basosquamous histology, and perineural invasion. [11][23]
- Reserve topical and destructive approaches for carefully selected low-risk superficial BCC; photodynamic therapy is an option for superficial and low-risk nodular tumors. [4][6]
- For locally advanced or metastatic BCC not amenable to curative local therapy, use a Hedgehog pathway inhibitor; cemiplimab is FDA-indicated after prior Hedgehog inhibitor therapy or when a Hedgehog inhibitor is not appropriate. [1][6][17]

## Confirm BCC and identify features that change local treatment

Document features that determine whether definitive treatment requires conventional or margin-controlled surgery.

Perform focused lesion examination with dermoscopy and document greatest clinical diameter, anatomic site, border definition, prior treatment, and whether the lesion is primary or recurrent. Dermoscopy is useful for BCC diagnosis and may help predict histopathologic subtype, but biopsy is required when clinical and dermoscopic findings are equivocal. [5][15]

Choose a biopsy approach that will provide histologic confirmation and subtype information without compromising definitive management. The pathology report should be reviewed specifically for aggressive growth patterns—morpheaform, infiltrative, micronodular, or basosquamous differentiation—and for perineural invasion, because each shifts management toward complete margin assessment and closer surveillance. [11][12][23]

Do not use routine TNM staging for ordinary localized BCC. Formal staging or additional extent assessment becomes relevant when there is advanced local disease, suspected nodal or distant disease, or concern for invasion of parotid gland, muscle, deep soft tissue, orbit, bone, or perineural structures. In these settings, obtain preoperative imaging directed to the threatened structure and plan treatment with dermatologic surgery, surgical oncology, radiation oncology, or a multidisciplinary tumor board. [11][12]
- Record prior BCCs and perform a complete skin examination; patients with one skin cancer remain at increased risk for additional skin cancers and precancerous lesions. [11]
- Use photographic or digital site documentation when following multiple lesions, recurrent tumors, or patients with extensive field cancerization. [11]
- Treat neurologic symptoms, radiologic perineural involvement, or pathology-confirmed perineural invasion as escalation triggers because perineural spread can extend beyond clinically apparent margins. [12]

*Clinical and histologic features that favor margin-controlled management or assessment for deeper extension. [11][12][23]*

| Finding | Interpretation | Next action |
| --- | --- | --- |
| Diameter >2 cm | High-risk recurrence feature. [11][23] | Plan definitive surgical clearance; assess whether location or extent favors micrographic surgery. [6][11] |
| Central face, ear, or scalp | High-risk location; central facial and auricular tumors have increased recurrence concern. [11][23] | Favor micrographically controlled surgery when feasible. [6] |
| Poorly defined borders or recurrent tumor | Clinical features associated with higher recurrence risk and occult extension. [11] | Use margin-controlled surgery rather than destructive treatment. [6][11] |
| Morpheaform, infiltrative, micronodular, or basosquamous subtype | Aggressive histology associated with high-risk behavior. [11][23] | Use complete margin assessment; discuss difficult cases in a multidisciplinary setting. [6] |
| Perineural invasion or symptoms suggesting neural involvement | May indicate deeper extension beyond visible margins. [12] | Obtain anatomy-directed imaging when clinically indicated and coordinate multidisciplinary treatment. [11][12] |

## Match treatment to recurrence risk, anatomy, and need for margin control

Surgical clearance is the default; nonsurgical therapy is a selection-dependent alternative rather than a substitute for high-risk disease control.

Offer complete surgery as first-line treatment for BCC. For high-risk or recurrent tumors and tumors at critical anatomic sites, micrographically controlled surgery should be offered because it provides real-time margin assessment while preserving uninvolved tissue. [5][6]

Use conventional surgical excision with margin evaluation for appropriately selected localized tumors when anatomic location and histology do not require micrographic control. Surgery, including standard excision and Mohs micrographic surgery, is the principal curative approach for localized BCC; reported recurrence-free rates across properly selected local modalities range from 85% to 95%. [3][17]

Restrict curettage and electrodesiccation, cryotherapy, topical imiquimod, topical 5-fluorouracil, and other destructive approaches to low-risk superficial BCC when histologic margin control is not required. These modalities should not be used as routine therapy for recurrent, poorly defined, aggressive-subtype, or critical-site tumors because they do not provide the same complete margin assessment. [4][6][17]

Consider photodynamic therapy for superficial BCC and selected low-risk nodular BCC when surgery is not preferred or when a nonsurgical approach is appropriate. The tradeoff is that surgery remains standard first-line treatment, whereas photodynamic therapy is a selection-dependent alternative for low-risk disease. [6][17]
- Use radiotherapy as a definitive local alternative for patients who are not surgical candidates or who decline surgery. [5][6][17]
- After incomplete excision or clinically evident recurrence, reassess histology, site, and extent rather than repeating a low-control modality; recurrent disease is a specific indication to favor micrographically controlled surgery. [6][11]
- Refer difficult-to-treat BCC—particularly lesions threatening orbit, bone, major nerves, or functionally critical structures—for multidisciplinary discussion before committing to morbid surgery, radiotherapy, or systemic therapy. [5][6]

*Local-treatment selection for BCC. [4][5][6][17]*

| Clinical setting | Preferred approach | Alternative or limiting consideration |
| --- | --- | --- |
| Most primary localized BCC | Complete surgical excision. [5][6] | Conventional excision is appropriate when complete margins can be obtained without a need for micrographic control. [17] |
| High-risk, recurrent, or critical-site BCC | Micrographically controlled surgery. [5][6] | Use multidisciplinary planning if extent threatens function or major structures. [5][6] |
| Low-risk superficial BCC | Topical imiquimod, topical 5-fluorouracil, or destructive therapy can be considered. [4][6][17] | Avoid these approaches when aggressive histology, recurrence, poorly defined borders, or critical-site location requires margin control. [6][11] |
| Superficial or low-risk nodular BCC | Photodynamic therapy can be effective. [6] | Surgery remains standard first-line therapy. [5][6] |
| Declines surgery or is not a surgical candidate | Radiotherapy is a valid local alternative. [5][6][17] | Do not use radiotherapy as a substitute for appropriate surgical assessment when surgery is feasible and preferred. [6] |

## Escalate unresectable BCC to systemic therapy after determining whether curative local treatment remains feasible

Advanced BCC requires a resectability and radiation assessment before systemic treatment is selected.

Classify BCC as locally advanced when complete surgery or curative radiotherapy is not feasible without unacceptable morbidity, and as metastatic when nodal or distant spread is present. Before systemic therapy, define local extent with anatomy-directed imaging when deep soft tissue, muscle, parotid, orbit, bone, or perineural involvement is suspected. [11][17]

Offer a Hedgehog pathway inhibitor—vismodegib or sonidegib—for locally advanced or metastatic BCC. These agents are the recommended systemic first-line class for advanced disease; prolonged Smoothened inhibitor therapy can be followed by resistance. [6][20]

Use cemiplimab for adults with locally advanced or metastatic BCC previously treated with a Hedgehog pathway inhibitor or for whom a Hedgehog pathway inhibitor is not appropriate. The FDA indication is supported by Study 1620, which enrolled advanced BCC after progression on a Hedgehog inhibitor, absence of objective response after 9 months of Hedgehog inhibitor therapy, or intolerance of prior Hedgehog inhibitor therapy. [1][2]

Assess immunotherapy candidacy carefully in patients with prior solid-organ transplantation, active autoimmune disease requiring systemic immunosuppression, or chronic viral infection because these populations were excluded from the pivotal advanced-BCC cemiplimab study. Discuss systemic treatment selection in a multidisciplinary setting when local therapy, radiation, and drug toxicities have competing functional consequences. [1][5][6]
- Do not default to cemiplimab before determining whether Hedgehog inhibition is contraindicated, inappropriate, intolerable, or unsuccessful; cemiplimab is positioned after or instead of Hedgehog inhibition under its FDA indication. [1][2]
- Reassess resectability and local-control options after systemic response when organ-preserving surgery or radiation may become feasible; difficult-to-treat disease warrants tumor-board review. [5][6]
- Document performance status and comorbidities before systemic treatment; Study 1620 excluded patients with ECOG performance status 2 or greater. [1]

*Systemic-therapy pathway for advanced BCC. [1][2][6][20]*

| Situation | Systemic option | Decision constraint |
| --- | --- | --- |
| Locally advanced or metastatic BCC not curable with local modalities | Hedgehog pathway inhibitor: vismodegib or sonidegib. [6][20] | Consider potential resistance with prolonged Smoothened inhibitor therapy. [20] |
| Progression during Hedgehog inhibitor therapy | Cemiplimab. [1][2][6] | FDA-indicated for locally advanced or metastatic BCC after prior Hedgehog inhibitor treatment. [1][2] |
| No objective response after 9 months of Hedgehog inhibitor therapy | Cemiplimab may be used. [1][2] | This criterion was included in the advanced-BCC cemiplimab study population. [1][2] |
| Hedgehog inhibitor intolerance, contraindication, or inappropriateness | Cemiplimab. [1][2][6] | Evaluate autoimmune disease, transplant history, and immunosuppression in treatment planning. [1] |

## Use lifelong skin surveillance and a low biopsy threshold for new or recurrent lesions

Follow-up should target local recurrence, new keratinocyte cancers, and delayed recognition of high-risk extension.

Perform long-term, often lifelong follow-up after BCC, with closer surveillance for patients with multiple, recurrent, or high-risk tumors. At each visit, examine the treated site for recurrence and perform a complete skin examination because subsequent skin cancers and precancerous lesions are common in this population. [11]

Maintain a low threshold to biopsy a new lesion within or adjacent to a prior treatment site, especially after topical, destructive, or radiation-based treatment where histologic margins were not assessed. Recurrent BCC, poorly defined borders, and aggressive histology should redirect management to complete margin-controlled treatment rather than repeated empiric destructive therapy. [6][11]

For tumors with perineural invasion, monitor for new pain, paresthesia, weakness, or other focal neurologic symptoms and obtain imaging when symptoms or examination raise concern for clinical perineural spread. Perineural invasion can precede symptoms and is associated with a greater likelihood of extension beyond surgical margins. [12]
- Document treated sites photographically when recurrence detection will be clinically difficult or when patients have multiple prior BCCs. [11]
- Reassess for deep-structure involvement before reoperation when recurrent disease involves the central face, ear, scalp, orbit, parotid region, or a symptomatic nerve distribution. [11][12]
- Continue surveillance after systemic therapy because advanced BCC management may require sequential systemic, surgical, and radiation decisions. [5][6]

*Surveillance triggers that require a change in management. [11][12]*

| Follow-up finding | Interpretation | Action |
| --- | --- | --- |
| New lesion or change at a prior treatment site | Possible local recurrence or new primary BCC. [11] | Perform prompt clinical assessment and maintain a low threshold for biopsy. [11] |
| Recurrent lesion with poorly defined borders | Higher-risk local behavior. [11] | Plan margin-controlled surgery when feasible. [6][11] |
| Pain, paresthesia, weakness, or other focal neurologic symptom | Possible clinical perineural involvement. [12] | Obtain directed imaging and coordinate multidisciplinary management. [11][12] |
| Multiple or high-risk prior BCCs | Persistent risk for additional skin cancers. [11] | Continue long-term complete skin examinations and lesion-site documentation. [11] |

## References
1. These highlights do not include all the information needed to use LIBTAYO safely and effectively. See full prescribing information for LIBTAYO. 
       LIBTAYO® (cemiplimab-rwlc) injection, for intravenous use  Initial U.S. Approval: 2018 — dailymed.nlm.nih.gov — https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=4347ae1f-d397-4f18-8b70-03897e1c054a
2. LIBTAYO — dailymed.nlm.nih.gov — https://dailymed.nlm.nih.gov/dailymed/getFile.cfm?setid=4347ae1f-d397-4f18-8b70-03897e1c054a&type=pdf
3. Guidelines of care for the management of basal cell carcinoma — www.sciencedirect.com — https://www.sciencedirect.com/science/article/abs/pii/S019096221732529X
4. Diagnosis and treatment of basal cell carcinoma: European consensus–based interdisciplinary guidelines - ScienceDirect — www.sciencedirect.com — https://www.sciencedirect.com/science/article/pii/S0959804919303624
5. Current management of nonmelanoma skin cancers — www.sciencedirect.com — https://www.sciencedirect.com/science/article/pii/S0011384024001266
6. European consensus-based interdisciplinary guideline for diagnosis and treatment of basal cell carcinoma—update 2023 — www.sciencedirect.com — https://www.sciencedirect.com/science/article/pii/S0959804923003568
7. Beyond Mohs surgery and excisions: A focused review of treatment options for subtypes of basal cell carcinoma - Altun - 2021 - Dermatologic Therapy - Wiley Online Library — onlinelibrary.wiley.com — https://onlinelibrary.wiley.com/doi/abs/10.1111/dth.14476
8. Keratinocytic skin cancers—Update on the molecular biology — acsjournals.onlinelibrary.wiley.com — https://acsjournals.onlinelibrary.wiley.com/doi/full/10.1002/cncr.34635
9. Known and new facts on basal cell carcinoma — onlinelibrary.wiley.com — https://onlinelibrary.wiley.com/doi/full/10.1111/ddg.14580
10. Comprehensive Insights Into Basal Cell Carcinoma — onlinelibrary.wiley.com — https://onlinelibrary.wiley.com/doi/pdf/10.1002/cam4.71448
11. Basal Cell Carcinoma - StatPearls - NCBI Bookshelf — www.ncbi.nlm.nih.gov — https://www.ncbi.nlm.nih.gov/books/NBK482439
12. Basal Cell Carcinoma Perineural Invasion and Suggestive Signs of Perineural Invasion—Findings and Perspectives — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC10303443
13. Basal Cell Carcinoma — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC3385325
14. Management Approaches for High-Risk Cutaneous Squamous Cell Carcinoma with Perineural Invasion: An Updated Review - PMC — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC11416415
15. The relation between dermoscopy and histopathology of basal ... — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC4516090
16. Cutaneous Squamous Cell Carcinoma - StatPearls - NCBI Bookshelf — www.ncbi.nlm.nih.gov — https://www.ncbi.nlm.nih.gov/books/NBK441939
17. Skin Cancer Treatment (PDQ®) - NCI — tools.cdc.gov — https://tools.cdc.gov/podcasts/download.asp?m=343872&c=343882
18. Basal cell carcinoma: an evidence-based treatment update — pubmed.ncbi.nlm.nih.gov — https://pubmed.ncbi.nlm.nih.gov/24733429
19. Results - Treatments for Basal Cell and Squamous Cell Carcinoma of the Skin - NCBI Bookshelf — www.ncbi.nlm.nih.gov — https://www.ncbi.nlm.nih.gov/books/NBK487557
20. Evaluation and Treatment of Skin Cancer in Patients With Immunosuppression - StatPearls - NCBI Bookshelf — www.ncbi.nlm.nih.gov — https://www.ncbi.nlm.nih.gov/sites/books/n/statpearls/article-169493
21. Management of basal cell carcinoma with pulmonary ... — pubmed.ncbi.nlm.nih.gov — https://pubmed.ncbi.nlm.nih.gov/36599494
22. Guidelines for the diagnosis and treatment of basal cell carcinoma: a GRADE approach for evidence evaluation and recommendations by the Italian Association of Medical Oncology — www.sciencedirect.com — https://www.sciencedirect.com/science/article/pii/S2059702923012784
23. Basal Cell Carcinoma Cell - an overview — www.sciencedirect.com — https://www.sciencedirect.com/topics/medicine-and-dentistry/basal-cell-carcinoma-cell
24. European interdisciplinary guideline on invasive squamous cell carcinoma of the skin: Part 1. epidemiology, diagnostics and prevention — www.sciencedirect.com — https://www.sciencedirect.com/science/article/pii/S0959804920300186

## Editorial note

Prepared from cited clinical literature using Astra's research workflow. Verify recommendations against current guidance and patient-specific factors.